I’m out of jury duty.... we won’t see direct revenue from Malta deal what we will see if Cannepil in Europe quicker because of Malta deal. Malta is a huge European port, MGC now has another direct tie in Europe. Cannepil will bring in $1,000,000 with under 100 of the fiat users. MGC has deals with 2 large pharmacy chains. With the Malta deal the Cannepil consumer base went from 70,000 in Australia to 300,000 with Europe combined.... this year!
If they only get 1% which I highly doubt (Cannepil is cheaper than current meds that don’t work) we are talking a $30,000,000 revenue stream.
That $30,000,000 - with the Nutra line, Derma, CBD contracts, Cult Beauty they could easily take in another $10,000,000- that’s low balling—— I didn’t even add the $40mil VC deal.
Their annual revenue will be more in 2018 than Canopy, Aurora and Alphria..... look st the market caps of those 3 companies. This opportunity I think is once in a life time
I’m gojng to go through the filings of MGC and the last quarterly sales of the 3 Canadian and get better numbers.... after I write my email
Market Data 
Markets 
AI
